ATM and ovarian carcinoma: In total, 10 Traceback testing participants received pathogenic or likely pathogenic results, representing a positive rate of 8% of people completing testing and 3% of all confirmed eligible for Traceback testing, including seven with a pathogenic variant in a gene with strong or definitive evidence of association with ovarian cancer (ATM [2], BRCA1 [1], BRCA2 [2], RAD51D [2]; range of pathogenic findings across sites was 5–9% of people completing testing; Table 3).